



SUVEN Life Sciences Ltd

Communication to investors **September 2017**

11-Nov-17

2017-18 Q2 results



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.



FINANCIAL QUICK VIEW

	FY 2017-18 Q2 to Q1	FY 2017-18 YoY (6 months)
Growth in revenue	-23.63%	-0.54%
Growth in PAT	7.37%	4.01%
Growth in EBIDTA	-1.54%	10.56%
Growth in Pre-R&D EBIDTA	-7.67%	6.61%
Increase in R&D Costs	-27.17%	-5.69%
R&D to sales	10.41%	10.70%





MAJOR PROFITABILITY RATIOS



	Q2 Sep 17	HY Sep 17
PAT to Income	28.33%	23.69%
EBIDTA to Income	44.74%	39.05%
Cash Flow to Income	33.09%	27.76%
Pre-R&D EBITDA to Income	55.15%	49.75%




Q2 to Q1 COMPARISON





REVENUE COMPARISON




11-Nov-17

2017-18 Q2 results




PAT COMPARISON






EBIDTA COMPARISON






R & D – EXPENDITURE





PRE-R&D EBIDTA




11-Nov-17

2017-18 Q2 results



PRE-R&D CASHFLOW



11-Nov-17

2017-18 Q2 results



FINANCIAL SNAPSHOT

All figures are in INR Million, other than ratios and EPS

	2017-18 Q2	2017-18 Q1	Growth %	2016-17 Q2	Growth %	2017-18 HY	2016-17 HY	Growth %
Income	1,119.91	1,466.42	-23.63%	1,223.05	-8.43%	2,586.33	2,600.29	-0.54%
Pre-R&D EBITDA	617.65	668.97	-7.67%	581.77	6.17%	1,286.62	1,206.85	6.61%
Pre-R&D EBITDA Margin %	55.15%	45.62%		47.57%		49.75%	46.41%	
EBITDA	501.03	508.86	-1.54%	435.23	15.12%	1,009.89	913.41	10.56%
EBITDA Margin %	44.74%	34.70%		35.59%		39.05%	35.13%	
EBIT	447.63	456.94	-2.04%	389.71	14.86%	904.57	819.83	10.34%
EBIT Margin %	39.97%	31.16%		31.86%		34.98%	31.53%	
Financing costs	9.36	12.70		12.37		22.06	28.33	
Taxes	121.05	148.77		112.89		269.82	202.43	
Net Profit after tax	317.23	295.46	7.37%	264.44	19.96%	612.69	589.07	4.01%
NP Margin %	28.33%	20.15%		21.62%		23.69%	22.65%	
EPS (basic & diluted not annualised)	2.09	2.56		1.98		4.65	3.60	
Paid up share capital (One Rupee Share)	127.28	127.28		127.28		127.28	127.28	
Depreciation	53.40	51.92		45.52		105.32	93.58	
R&D expenses	116.61	160.12	-27.17%	146.54	-20.42%	276.73	293.44	-5.69%

News Release



- During the period Suven secures 5 product patents covering Singapore, New Zealand, India and Japan and 3 process patents covering Europe, Japan and New Zealand.
- Updates on CRAMS projects: Total – 116; Phase 1 – 73, Phase 2 – 38, Phase 3 – 2 and commercial – 3.
- Suven participated in CPhI Worldwide exhibition held in October 2017 in Frankfurt, Germany.
- Suven participated in CTAD (Clinical Trial on Alzheimer's Disease) held in November 2017 in Boston, USA.